Ovarian Hyperstimulation Syndrome: Clinical Trials

7 trials for Ovarian Hyperstimulation Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 unknown. 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 37Completed 4, Unknown 3

Follow Ovarian Hyperstimulation Syndrome: new trials by email Literature Review of Ovarian Hyperstimulation Syndrome trials Research Report on Ovarian Hyperstimulation Syndrome

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Letrozole Administration During Luteal Phase
Letrozole, Polygeline, Sodium Chloride - Ovarian Hyperstimulation Syndrome
Phase 3UnknownThe Affiliated Hospital of Inner Mongolia Medical University502023-12-012023-07-20
The Influence of Timing of Cabergoline Initiation on Prevention of OHSS
Late Cabergoline 0.5mg, Early Cabergoline 0.5mg - Ovarian Hyperstimulation Syndrome
Phase 3UnknownMona M Shaban752017-12-202018-04-10
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
Triptorelin for Injection, Recombinant Human Choriogonadotropin alfa Solution for Injection, Progesterone Soft Capsules - Ovarian Hyperstimulation Syndrome
Phase 3UnknownChangchun GeneScience Pharmaceutical Co., Ltd.2522017-03-012017-03-06
GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome
GnRH antagonist (Cetrorelix), Placebo (saline solution) - Ovarian Hyperstimulation Syndrome, Effects of Gonadotropin
Phase 3CompletedInstituto Valenciano de Infertilidad, IVI VALENCIA1002012-04-012013-09-19
Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
Cabergoline, Placebo - Ovarian Hyperstimulation Syndrome
Phase 3CompletedKK Women's and Children's Hospital462012-04-012018-08-07
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
calcium, 0.9 % saline - Ovarian Hyperstimulation Syndrome
Phase 3CompletedCairo University2002011-10-012014-07-09
Cabergoline Reduces OHSS
Cabergoline, MR, Ultrasound - Ovarian Hyperstimulation Syndrome
Phase 3CompletedInstituto Valenciano de Infertilidad, IVI VALENCIA602004-04-012007-02-27

Narrower conditions

Ascites (1)

Broader conditions

Adnexal Diseases (7)  ·  Endocrine System Diseases (7)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Genital Diseases (7)  ·  Genital Diseases, Female (7)  ·  Gonadal Disorders (7)  ·  Ovarian Diseases (7)  ·  Urogenital Diseases (7)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Cabergoline (3)  ·  Sodium Chloride (2)  ·  Calcium (1)  ·  Dexamethasone (1)  ·  Hematologic Tests (1)  ·  High-Energy Shock Waves (1)  ·  Injections (1)  ·  Letrozole (1)  ·  Polygeline (1)  ·  Saline Solution (1)  ·  Triptorelin Pamoate (1)  ·  cetrorelix (1)

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA (2)  ·  Cairo University (1)  ·  Changchun GeneScience Pharmaceutical Co., Ltd. (1)  ·  KK Women's and Children's Hospital (1)  ·  Mona M Shaban (1)  ·  The Affiliated Hospital of Inner Mongolia Medical University (1)

Countries

China (2)  ·  Egypt (2)  ·  Singapore (1)  ·  Spain (1)

Top investigators

Antonio Pellicer, MD (1)  ·  Juan Giles, MD (1)  ·  Marianne Sybille Hendricks, MBBS, MRCOG (1)  ·  Mona M Shaban, MD (1)  ·  Rong Li, Doctor (1)  ·  Waleed M El-Khayat, M.D. (1)  ·  Xiujuan Chen, MD (1)  ·  Yu Wang, PhD (1)

Results publications

PMID 25552412, PMID 33851429